Dr. Borgen Discusses HER2 Blockade in Breast Cancer

Patrick Borgen, MD
Published: Wednesday, Feb 21, 2018



Patrick Borgen, MD, chair, Department of Surgery, director, Breast Center, Maimonides Medical Center, discusses HER2 blockade in the treatment of patients with HER2-positive breast cancer.

One of the questions that comes up with HER2-positive breast cancers, is at what tumor size in the node-negative setting should HER2 blockade be considered? Borgen says that for small tumors that are otherwise favorable, patients should receive a taxane and trastuzumab (Herceptin), based on the survival rate from the APT trial in patients with early-stage breast cancers that were HER2-positive. These are patients who are not going to need multimodal cytotoxic therapy or targeting of HER2, as this adjuvant regimen induced a 97% 5-year disease-free survival in the APT trial.  

For patients with tumors that are 5 mm, HER2 blockade might be considered. For patients with tumors that exceed 6 mm, HER2 blockade should absolutely be used, Borgen says.


Patrick Borgen, MD, chair, Department of Surgery, director, Breast Center, Maimonides Medical Center, discusses HER2 blockade in the treatment of patients with HER2-positive breast cancer.

One of the questions that comes up with HER2-positive breast cancers, is at what tumor size in the node-negative setting should HER2 blockade be considered? Borgen says that for small tumors that are otherwise favorable, patients should receive a taxane and trastuzumab (Herceptin), based on the survival rate from the APT trial in patients with early-stage breast cancers that were HER2-positive. These are patients who are not going to need multimodal cytotoxic therapy or targeting of HER2, as this adjuvant regimen induced a 97% 5-year disease-free survival in the APT trial.  

For patients with tumors that are 5 mm, HER2 blockade might be considered. For patients with tumors that exceed 6 mm, HER2 blockade should absolutely be used, Borgen says.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x